<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240326221510&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240326221510&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 27 Mar 2024 02:15:11 +0000</lastbuilddate>
<pubDate>Tue, 26 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Third time's a harm? Cardiac risk of SARS-CoV-2 mRNA booster vaccines in younger men</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38531026/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 26:ehae157. doi: 10.1093/eurheartj/ehae157. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38531026/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38531026</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae157>10.1093/eurheartj/ehae157</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38531026</guid>
<pubDate>Tue, 26 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Leslie T Cooper</dc:creator>
<dc:creator>Tal Hasin</dc:creator>
<dc:creator>Margaret Ryan</dc:creator>
<dc:date>2024-03-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Third time's a harm? Cardiac risk of SARS-CoV-2 mRNA booster vaccines in younger men</dc:title>
<dc:identifier>pmid:38531026</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae157</dc:identifier>
</item>
<item>
<title>Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38530688/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SGLT2i generally seem safe, well-tolerated, and potentially beneficial in patients with ACHD. SGLT2i was associated with a 3-fold reduction in the 6-month HF hospitalization rate. These results warrant prospective randomized investigation of the potential benefits of SGLT2i for patients with ACHD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 12:S0735-1097(24)00385-1. doi: 10.1016/j.jacc.2024.02.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF) is the principal cause of morbidity and mortality in adults with congenital heart disease (ACHD). Robust evidence-based treatment options are lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to evaluate the safety, tolerability, and short-term HF-related effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in a real-world ACHD population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All patients with ACHD treated with SGLT2i in 4 European ACHD centers were included in this retrospective study. Data were collected from 1 year before starting SGLT2i to the most recent follow-up. Data on side effects, discontinuation, mortality, and hospitalizations were collected.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 174 patients with ACHD were treated with SGLT2i from April 2016 to July 2023. The mean age was 48.7 ± 15.3 years, 72 (41.4%) were female, and 29 (16.7%) had type 2 diabetes mellitus. Ten (5.7%) patients had mild, 75 (43.1%) moderate, and 89 (51.1%) severe congenital heart disease. HF was the most frequent starting indication (n = 162, 93.1%), followed by type 2 diabetes (n = 11, 6.3%) and chronic kidney disease (n = 1, 0.6%). At median follow-up of 7.7 months (Q1-Q3: 3.9-13.2 months), 18 patients (10.3%) reported side effects, 12 (6.9%) permanently discontinued SGLT2i, and 4 (2.3%) died of SGLT2i-unrelated causes. A significant reduction in the HF hospitalization rate was observed from 6 months before to 6 months after starting SGLT2i (relative rate = 0.30; 95% CI: 0.14-0.62; P = 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SGLT2i generally seem safe, well-tolerated, and potentially beneficial in patients with ACHD. SGLT2i was associated with a 3-fold reduction in the 6-month HF hospitalization rate. These results warrant prospective randomized investigation of the potential benefits of SGLT2i for patients with ACHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38530688/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38530688</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.017>10.1016/j.jacc.2024.02.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38530688</guid>
<pubDate>Tue, 26 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ralph M L Neijenhuis</dc:creator>
<dc:creator>Simon T MacDonald</dc:creator>
<dc:creator>Filip Zemrak</dc:creator>
<dc:creator>Bart J A Mertens</dc:creator>
<dc:creator>Anna Dinsdale</dc:creator>
<dc:creator>Amanda Hunter</dc:creator>
<dc:creator>Niki L Walker</dc:creator>
<dc:creator>Lorna Swan</dc:creator>
<dc:creator>Sushma Reddy</dc:creator>
<dc:creator>Joris I Rotmans</dc:creator>
<dc:creator>J Wouter Jukema</dc:creator>
<dc:creator>Monique R M Jongbloed</dc:creator>
<dc:creator>Gruschen R Veldtman</dc:creator>
<dc:creator>Anastasia D Egorova</dc:creator>
<dc:date>2024-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:38530688</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.017</dc:identifier>
</item>
<item>
<title>The Natural History of Atrial Functional Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38530687/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with predominantly mild-moderate/moderate AFMR, regression of MR was more common than progression, but neither was associated with mortality. Instead, diastolic function abnormalities were more important. Over a median 2-year follow-up, LVSD risk was not increased.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 17:S0735-1097(24)00413-3. doi: 10.1016/j.jacc.2024.02.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The natural history of moderate/severe atrial functional mitral regurgitation (AFMR) is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to study the incidence of left ventricular (LV) systolic dysfunction (LVSD), progression or regression of ≥mild-moderate AFMR, and impact on mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Adults with left atrial (LA) volume index ≥40 mL/m<sup>2</sup>, ≥mild-moderate AFMR, and follow-up echocardiogram were followed for incident LVSD (ejection fraction &lt;50% and ≥10% lower than baseline), progression of mild-moderate/moderate AFMR to severe, and persistent regression of AFMR to no/trivial. Relation of AFMR progression or regression as time-dependent covariates with all-cause mortality was studied. Incidence of LVSD was compared with patients with no/mild AFMR matched on age, sex, comorbidities and ejection fraction. Patients were followed until mitral intervention, myocardial infarction, or last follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 635 patients (median age 75 years, 51% female, 96% mild-moderate/moderate AFMR, 4% severe AFMR) were included. Over a median 2.2 years (Q1-Q3: 1.0-4.3 years), incidence rates per 100 person-years were 3.2 for LVSD (P = 0.52 vs patients with no/mild AFMR), 1.9 for progression of AFMR, and 3.9 for regression. Female sex and larger LA volume index were independently associated with progression, whereas younger age, male sex, absent atrial fibrillation, and higher LA emptying fraction were independently associated with regression. Neither AFMR progression nor regression was independently associated with mortality. Instead, independent risk factors for mortality included older age, concentric LV geometry, and higher estimated LV filling and pulmonary pressures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with predominantly mild-moderate/moderate AFMR, regression of MR was more common than progression, but neither was associated with mortality. Instead, diastolic function abnormalities were more important. Over a median 2-year follow-up, LVSD risk was not increased.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38530687/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38530687</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.026>10.1016/j.jacc.2024.02.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38530687</guid>
<pubDate>Tue, 26 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Jwan A Naser</dc:creator>
<dc:creator>Francisco B Alexandrino</dc:creator>
<dc:creator>Tomonari Harada</dc:creator>
<dc:creator>Hector I Michelena</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Mackram F Eleid</dc:creator>
<dc:creator>Grace Lin</dc:creator>
<dc:creator>Christopher Scott</dc:creator>
<dc:creator>Austin M Kennedy</dc:creator>
<dc:creator>Patricia A Pellikka</dc:creator>
<dc:creator>Vuyisile T Nkomo</dc:creator>
<dc:creator>Sorin V Pislaru</dc:creator>
<dc:date>2024-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Natural History of Atrial Functional Mitral Regurgitation</dc:title>
<dc:identifier>pmid:38530687</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.026</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38530686/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Baseline Lp(a) concentration was prognostic for MACE among participants with elevated triglyceride levels receiving statin therapy. Importantly, IPE consistently reduced MACE across a range of Lp(a) levels, including among those with clinically relevant elevations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 15:S0735-1097(24)00384-X. doi: 10.1016/j.jacc.2024.02.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Elevated lipoprotein(a) (Lp[a]) concentrations are associated with increased cardiovascular event risk even in the presence of well-controlled low-density lipoprotein cholesterol levels, but few treatments are documented to reduce this residual risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this post hoc analysis of REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was to explore the cardiovascular benefit of icosapent ethyl (IPE) across a range of Lp(a) levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 8,179 participants receiving statin therapy with established cardiovascular disease or age ≥50 years with diabetes and ≥1 additional risk factor, fasting triglyceride 1.69 to 5.63 mmol/L, and low-density lipoprotein cholesterol 1.06 to 2.59 mmol/L were randomized to receive 2 g twice daily of IPE or matching placebo. Relationships between continuous baseline Lp(a) mass concentration and risk for first and total (first and subsequent) major adverse cardiovascular events (MACE) were analyzed, along with the effects of IPE on first MACE among those with Lp(a) concentrations ≥50 or &lt;50 mg/dL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 7,026 participants (86% of those randomized) with baseline Lp(a) assessments, the median concentration was 11.6 mg/dL (Q1-Q3: 5.0-37.4 mg/dL). Lp(a) had significant relationships with first and total MACE (P &lt; 0.0001), while event reductions with IPE did not vary across the range of Lp(a) (interaction P >; 0.10). IPE significantly reduced first MACE in subgroups with concentrations ≥50 and &lt;50 mg/dL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Baseline Lp(a) concentration was prognostic for MACE among participants with elevated triglyceride levels receiving statin therapy. Importantly, IPE consistently reduced MACE across a range of Lp(a) levels, including among those with clinically relevant elevations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38530686/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38530686</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.016>10.1016/j.jacc.2024.02.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38530686</guid>
<pubDate>Tue, 26 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael Szarek</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Michael Miller</dc:creator>
<dc:creator>Eliot A Brinton</dc:creator>
<dc:creator>Terry A Jacobson</dc:creator>
<dc:creator>Jean-Claude Tardif</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>R Preston Mason</dc:creator>
<dc:creator>Steven B Ketchum</dc:creator>
<dc:creator>Armando Lira Pineda</dc:creator>
<dc:creator>Ralph T Doyle</dc:creator>
<dc:creator>Ph Gabriel Steg</dc:creator>
<dc:creator>REDUCE-IT Investigators</dc:creator>
<dc:date>2024-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl</dc:title>
<dc:identifier>pmid:38530686</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.016</dc:identifier>
</item>
<item>
<title>Defining Disease Progression in ATTR Cardiac Amyloidosis: Keeping It Simple</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38530685/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 6:S0735-1097(24)00409-1. doi: 10.1016/j.jacc.2024.02.024. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38530685/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38530685</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.024>10.1016/j.jacc.2024.02.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38530685</guid>
<pubDate>Tue, 26 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Kevin M Alexander</dc:creator>
<dc:date>2024-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Defining Disease Progression in ATTR Cardiac Amyloidosis: Keeping It Simple</dc:title>
<dc:identifier>pmid:38530685</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.024</dc:identifier>
</item>
<item>
<title>Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38530684/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: NT-proBNP progression and ODI are frequent and consistently associated with an increased risk of mortality. Combining both variables produces a simple, universally applicable model that detects disease progression in ATTR-CA.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 1:S0735-1097(24)00251-1. doi: 10.1016/j.jacc.2023.12.036. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyopathy. The clinical course varies among individuals and there are no established measures to assess disease progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to assess the prognostic importance of an increase in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and outpatient diuretic intensification (ODI) as markers of disease progression in a large cohort of patients with ATTR-CA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We evaluated landmark survival analysis based on worsening of NT-proBNP and requirement for ODI between time of diagnosis and a 1-year visit, and subsequent mortality in 2,275 patients with ATTR-CA from 7 specialist centers. The variables were developed in the National Amyloidosis Centre (NAC) cohort (n = 1,598) and validated in the external cohort from the remaining centers (n = 677).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between baseline and 1-year visits, 551 (34.5%) NAC patients and 204 (30.1%) patients in the external validation cohort experienced NT-proBNP progression (NT-proBNP increase >;700 ng/L and >;30%), which was associated with mortality (NAC cohort: HR: 1.82; 95% CI: 1.57-2.10; P &lt; 0.001; validation cohort: HR: 1.75; 95% CI: 1.32-2.33; P &lt; 0.001). At 1 year, 451 (28.2%) NAC patients and 301 (44.5%) patients in the external validation cohort experienced ODI, which was associated with mortality (NAC cohort: HR: 1.88; 95% CI: 1.62-2.18; P &lt; 0.001; validation cohort: HR: 2.05; 95% CI: 1.53-2.74; P &lt; 0.001). When compared with patients with a stable NT-proBNP and stable diuretic dose, a higher risk of mortality was observed in those experiencing either NT-proBNP progression or ODI (NAC cohort: HR: 1.93; 95% CI: 1.65-2.27; P &lt; 0.001; validation cohort: HR: 1.94; 95% CI: 1.36-2.77; P &lt; 0.001), and those experiencing both NT-proBNP progression and ODI (NAC cohort: HR: 2.98; 95% CI: 2.42-3.67; P &lt; 0.001; validation cohort: HR: 3.23; 95% CI: 2.17-4.79; P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: NT-proBNP progression and ODI are frequent and consistently associated with an increased risk of mortality. Combining both variables produces a simple, universally applicable model that detects disease progression in ATTR-CA.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38530684/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38530684</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.036>10.1016/j.jacc.2023.12.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38530684</guid>
<pubDate>Tue, 26 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Adam Ioannou</dc:creator>
<dc:creator>Francesco Cappelli</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:creator>Christian Nitsche</dc:creator>
<dc:creator>Simone Longhi</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Alberto Cipriani</dc:creator>
<dc:creator>Mattia Zampieri</dc:creator>
<dc:creator>Federica Colio</dc:creator>
<dc:creator>Michael Poledniczek</dc:creator>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Yousuf Razvi</dc:creator>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Giuseppe Vergaro</dc:creator>
<dc:creator>Laura De Michieli</dc:creator>
<dc:creator>Muhammad U Rauf</dc:creator>
<dc:creator>Rishi K Patel</dc:creator>
<dc:creator>Eugenia Villanueva</dc:creator>
<dc:creator>Yael Lustig</dc:creator>
<dc:creator>Lucia Venneri</dc:creator>
<dc:creator>Ana Martinez-Naharro</dc:creator>
<dc:creator>Helen Lachmann</dc:creator>
<dc:creator>Ashutosh Wechalekar</dc:creator>
<dc:creator>Carol Whelan</dc:creator>
<dc:creator>Aviva Petrie</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Scott Solomon</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2024-03-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis</dc:title>
<dc:identifier>pmid:38530684</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.036</dc:identifier>
</item>
<item>
<title>A deep learning solution to detect left ventricular structural abnormalities with chest X-rays: towards trustworthy AI in cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 25:ehad775. doi: 10.1093/eurheartj/ehad775. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527415</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad775>10.1093/eurheartj/ehad775</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527415</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Karim Lekadir</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A deep learning solution to detect left ventricular structural abnormalities with chest X-rays: towards trustworthy AI in cardiology</dc:title>
<dc:identifier>pmid:38527415</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad775</dc:identifier>
</item>
<item>
<title>Correction to: Healthcare resource utilisation and safety outcomes in patients undergoing transcatheter mitral valve repair - A nationwide analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 25:ehae168. doi: 10.1093/eurheartj/ehae168. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527371</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae168>10.1093/eurheartj/ehae168</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527371</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Healthcare resource utilisation and safety outcomes in patients undergoing transcatheter mitral valve repair - A nationwide analysis</dc:title>
<dc:identifier>pmid:38527371</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae168</dc:identifier>
</item>
<item>
<title>Can an implantable loop recorder improve risk stratification and appropriate management in Brugada syndrome?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527218/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 25:ehae136. doi: 10.1093/eurheartj/ehae136. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527218/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527218</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae136>10.1093/eurheartj/ehae136</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527218</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Fiorenzo Gaita</dc:creator>
<dc:creator>Natascia Cerrato</dc:creator>
<dc:creator>Carla Giustetto</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Can an implantable loop recorder improve risk stratification and appropriate management in Brugada syndrome?</dc:title>
<dc:identifier>pmid:38527218</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae136</dc:identifier>
</item>
<item>
<title>Subclinical Atrial Fibrillation and Anticoagulation: Weighing the Absolute Risks and Benefits</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527139/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):989-992. doi: 10.1161/CIRCULATIONAHA.123.067919. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527139/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527139</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067919>10.1161/CIRCULATIONAHA.123.067919</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527139</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Siddharth M Patel</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Subclinical Atrial Fibrillation and Anticoagulation: Weighing the Absolute Risks and Benefits</dc:title>
<dc:identifier>pmid:38527139</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067919</dc:identifier>
</item>
<item>
<title>Correction to: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527138/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1023. doi: 10.1161/CIR.0000000000001241. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527138/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527138</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001241>10.1161/CIR.0000000000001241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527138</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:38527138</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001241</dc:identifier>
</item>
<item>
<title>Retraction of: Abstract 13079: Prevalence and Incidence of Transthyretin Amyloid Cardiomyopathy in the USA From 2004 to 2022: An Observational Database Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527137/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1027. doi: 10.1161/CIR.0000000000001239. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527137/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527137</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001239>10.1161/CIR.0000000000001239</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527137</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Retraction of: Abstract 13079: Prevalence and Incidence of Transthyretin Amyloid Cardiomyopathy in the USA From 2004 to 2022: An Observational Database Study</dc:title>
<dc:identifier>pmid:38527137</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001239</dc:identifier>
</item>
<item>
<title>Atrial Fibrillation: Why Are We Hiding Reality?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527136/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):979-980. doi: 10.1161/CIRCULATIONAHA.123.067544. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527136/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527136</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067544>10.1161/CIRCULATIONAHA.123.067544</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527136</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>James A Reiffel</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Atrial Fibrillation: Why Are We Hiding Reality?</dc:title>
<dc:identifier>pmid:38527136</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067544</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18539</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1025. doi: 10.1161/CIR.0000000000001237. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527135</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001237>10.1161/CIR.0000000000001237</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527135</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18539</dc:title>
<dc:identifier>pmid:38527135</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001237</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 15684</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1024. doi: 10.1161/CIR.0000000000001238. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527134</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001238>10.1161/CIR.0000000000001238</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527134</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 15684</dc:title>
<dc:identifier>pmid:38527134</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001238</dc:identifier>
</item>
<item>
<title>Aggregation and Contextualization of Murine Investigations Improves Discovery of Significant Human Atherosclerotic Cardiovascular Disease Associations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):1056-1058. doi: 10.1161/CIRCULATIONAHA.123.067510. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527133</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067510>10.1161/CIRCULATIONAHA.123.067510</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527133</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Megan M Shuey</dc:creator>
<dc:creator>Yihua Wang</dc:creator>
<dc:creator>Rachel R Xiang</dc:creator>
<dc:creator>Aaron Zou</dc:creator>
<dc:creator>Protiva Rahman</dc:creator>
<dc:creator>Daniel Fabbri</dc:creator>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:creator>Iris Z Jaffe</dc:creator>
<dc:creator>Quinn S Wells</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Aggregation and Contextualization of Murine Investigations Improves Discovery of Significant Human Atherosclerotic Cardiovascular Disease Associations</dc:title>
<dc:identifier>pmid:38527133</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067510</dc:identifier>
</item>
<item>
<title>Don't Judge A Book By Its Cover</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):1053-1055. doi: 10.1161/CIRCULATIONAHA.123.068148. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527132</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068148>10.1161/CIRCULATIONAHA.123.068148</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527132</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Saurabh Deshpande</dc:creator>
<dc:creator>Rajesh Rajani</dc:creator>
<dc:creator>Ameya Udyavar</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Don't Judge A Book By Its Cover</dc:title>
<dc:identifier>pmid:38527132</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068148</dc:identifier>
</item>
<item>
<title>Correction to: International Collaboration Identifies Gene Linked to Congenital Heart Defect</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527131/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):e1026. doi: 10.1161/CIR.0000000000001236. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527131/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527131</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001236>10.1161/CIR.0000000000001236</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527131</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: International Collaboration Identifies Gene Linked to Congenital Heart Defect</dc:title>
<dc:identifier>pmid:38527131</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001236</dc:identifier>
</item>
<item>
<title>Scrutinizing the Role of Venoarterial Extracorporeal Membrane Oxygenation: Has Clinical Practice Outpaced the Evidence?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for temporary mechanical circulatory support in various clinical scenarios has been increasing consistently, despite the lack of sufficient evidence regarding its benefit and safety from adequately powered randomized controlled trials. Although the ARREST trial (Advanced Reperfusion Strategies for Patients with Out-of-Hospital Cardiac Arrest and Refractory Ventricular Fibrillation) and a secondary analysis of the PRAGUE OHCA...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):1033-1052. doi: 10.1161/CIRCULATIONAHA.123.067087. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for temporary mechanical circulatory support in various clinical scenarios has been increasing consistently, despite the lack of sufficient evidence regarding its benefit and safety from adequately powered randomized controlled trials. Although the ARREST trial (Advanced Reperfusion Strategies for Patients with Out-of-Hospital Cardiac Arrest and Refractory Ventricular Fibrillation) and a secondary analysis of the PRAGUE OHCA trial (Prague Out-of-Hospital Cardiac Arrest) provided some evidence in favor of VA-ECMO in the setting of out-of-hospital cardiac arrest, the INCEPTION trial (Early Initiation of Extracorporeal Life Support in Refractory Out-of-Hospital Cardiac Arrest) has not found a relevant improvement of short-term mortality with extracorporeal cardiopulmonary resuscitation. In addition, the results of the recently published ECLS-SHOCK trial (Extracorporeal Life Support in Cardiogenic Shock) and ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) discourage the routine use of VA-ECMO in patients with infarct-related cardiogenic shock. Ongoing clinical trials (ANCHOR [Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock, NCT04184635], REVERSE [Impella CP With VA ECMO for Cardiogenic Shock, NCT03431467], UNLOAD ECMO [Left Ventricular Unloading to Improve Outcome in Cardiogenic Shock Patients on VA-ECMO, NCT05577195], PIONEER [Hemodynamic Support With ECMO and IABP in Elective Complex High-risk PCI, NCT04045873]) may clarify the usefulness of VA-ECMO in specific patient subpopulations and the efficacy of combined mechanical circulatory support strategies. Pending further data to refine patient selection and management recommendations for VA-ECMO, it remains uncertain whether the present usage of this device improves outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527130</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067087>10.1161/CIRCULATIONAHA.123.067087</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527130</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Enzo Lüsebrink</dc:creator>
<dc:creator>Leonhard Binzenhöfer</dc:creator>
<dc:creator>Daniel Hering</dc:creator>
<dc:creator>Laura Villegas Sierra</dc:creator>
<dc:creator>Benedikt Schrage</dc:creator>
<dc:creator>Clemens Scherer</dc:creator>
<dc:creator>Walter S Speidl</dc:creator>
<dc:creator>Aitor Uribarri</dc:creator>
<dc:creator>Manel Sabate</dc:creator>
<dc:creator>Marko Noc</dc:creator>
<dc:creator>Elena Sandoval</dc:creator>
<dc:creator>Andrejs Erglis</dc:creator>
<dc:creator>Federico Pappalardo</dc:creator>
<dc:creator>Frederic De Roeck</dc:creator>
<dc:creator>Guido Tavazzi</dc:creator>
<dc:creator>Jordi Riera</dc:creator>
<dc:creator>Roberto Roncon-Albuquerque</dc:creator>
<dc:creator>Benjamin Meder</dc:creator>
<dc:creator>Peter Luedike</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>Christian Hagl</dc:creator>
<dc:creator>Sebastian Zimmer</dc:creator>
<dc:creator>Dirk Westermann</dc:creator>
<dc:creator>Alain Combes</dc:creator>
<dc:creator>Uwe Zeymer</dc:creator>
<dc:creator>Steffen Massberg</dc:creator>
<dc:creator>Andreas Schäfer</dc:creator>
<dc:creator>Martin Orban</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Scrutinizing the Role of Venoarterial Extracorporeal Membrane Oxygenation: Has Clinical Practice Outpaced the Evidence?</dc:title>
<dc:identifier>pmid:38527130</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067087</dc:identifier>
</item>
<item>
<title>How Can Young Extracellular Matrix Promote Cardiac Regeneration? Versi-Can!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527129/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):1016-1018. doi: 10.1161/CIRCULATIONAHA.123.068078. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527129/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527129</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068078>10.1161/CIRCULATIONAHA.123.068078</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527129</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Elad Bassat</dc:creator>
<dc:creator>Eldad Tzahor</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>How Can Young Extracellular Matrix Promote Cardiac Regeneration? Versi-Can!</dc:title>
<dc:identifier>pmid:38527129</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068078</dc:identifier>
</item>
<item>
<title>The American Heart Association's Centennial and Percutaneous Coronary Intervention's Semi-Centennial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38527128/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240326221510&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 26;149(13):973-978. doi: 10.1161/CIRCULATIONAHA.123.064461. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38527128/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240326221510&v=2.18.0.post9+e462414">38527128</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064461>10.1161/CIRCULATIONAHA.123.064461</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38527128</guid>
<pubDate>Mon, 25 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>Pruthvi C Revaiah</dc:creator>
<dc:date>2024-03-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The American Heart Association's Centennial and Percutaneous Coronary Intervention's Semi-Centennial</dc:title>
<dc:identifier>pmid:38527128</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064461</dc:identifier>
</item>





























</channel>
</rss>